DOMINO-HD

MULTI-DOMAIN LIFESTYLE TARGETS FOR IMPROVING PROGNOSIS IN HUNTINGTON’S DISEASE

Recruiting

ABOUT

SPONSOR

Cardiff University

PARTICIPANTS

300-450

DOMINO-HD is split into two phases; phase 1 is looking at methods for reliably measuring lifestyle factors (physical activity, sleep, diet) in people with Huntington’s disease (HD) in a way that disrupts their normal life as little as possible. Phase 2 will use the information gathered in phase 1 to measure these lifestyle factors in people with HD over 12 months. The main purpose of DOMINO-HD is to look at how sleep, nutrition and physical activity impacts the progression of Huntington´s disease so as to develop new ways to support and manage fundamental aspects of HD patients. The study will also explore how digital technologies, such as wearable fitness trackers, can be used to support people with HD.

Estimated Study Completion Date: September 2022

Ages Eligible for Study:

18 Years and older (Adult, Older Adult)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Gene positive

Inclusion Criteria

Adults (aged over 18 years) with a diagnosis of Huntington’s Disease confirmed by genetic testing, who are able to walk unassisted and are participating (current or newly enrolled) in the Enroll-HD study.

Exclusion Criteria

  • Diagnosis of juvenile onset Huntington’s Disease (HD)
  • History of co-morbid neurological conditions such as multiple sclerosis or stroke
  • Acute (within 1 month) orthopaedic conditions such as an ankle sprain or fracture
  • Severe medical conditions such as unstable or progressive heart disease, uncontrolled diabetes, severe liver, kidney or thyroid dysfunction, or similar medical conditions
  • Any acute or unstable psychiatric condition
  • Unable to tolerate long-term wear of activity monitor
  • Inability or unwillingness to give written informed consent
  • No access to a smartphone
  • Not willing to allow the research team to install Apps on their smartphone related to the study

COUNTRIES

General enquiries

Cheney Drew
Tel: +44 (0)29 2068 7243
drewc5@cardiff.ac.uk


UPDATES:

Recruitment for this EU-funded observational study, which is designed to provide new insights into whether behaviour and lifestyle factors are linked to HD genetic risk and progression, finally got underway in February following delays caused by the pandemic.

GERMANY

IRELAND

TRIAL SITE: 
Universitätsklinikum Ulm

Address: Ulm, Baden-Württemberg, Germany, 89081

CONTACT
Nana Kovacevic
nana.kovacevic@uniklinik-ulm.de

Recruiting

TRIAL SITE:
University College Dublin, Ireland

Address: University College Dublin, Belfield, Dublin 4, Irland

CONTACT
Madeleine Lowery
Tel: +353 1 716 1911
madeleine.lowery@ucd.ie

Recruiting

POLAND

SPAIN

TRIAL SITE:
Institute of Psychiatry and Neurology, Warsaw

Address: Jana III Sobieskiego 9, Warszawa, 02-957 

CONTACT
Malgorzata Dusza-Rowinska
Tel: +48 694 904 208
m.dusza.rowinska@gmail.com

Recruiting

TRIAL SITE:
Hospital Universitario de Burgos

Address: Neurology Department, Avda Islas Baleares 3, Burgos, 09006

CONTACT
Carla Collazo
Tel: 947 256 533 ext 35380
ccollazo@ubu.es

Recruiting

SWITZERLAND

UNITED KINGDOM

TRIAL SITE:
University Hospital Zurich

Address: Zürich, Switzerland, 08091

CONTACT
Hans Jung
hans.jung@usz.ch

Klavs Renerts
klavs.renerts@usz.ch

Recruiting

TRIAL SITE (Lead site):
Cardiff University

Address: Cardiff, United Kingdom, CF24 4HQ

CONTACT
Philippa Jones
Tel: +44 29206 87269
dominohd@cardiff.ac.uk

 

Recruiting